Sublingual misoprostol for management of empty sac or missed miscarriage: The first two years’ experience at a metropolitan Australian hospital

McGee, Therese; Diplock, Hayley; Lucewicz, Ania

doi:10.1111/ajo.12481

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 Our estimates of miscarriage treatment-related events, including the more than 6% retained products of conception, are in the range of other estimates. [24][25][26][27][28][29][30][31] The rates of miscarriage treatment-related events are notably higher than published rates of abortion-related events. 9,10,12,32,33 One explanation is that there have been both government sponsored and professional association sponsored clinical quality improvement initiatives for abortion for more than 40 years, [33][34][35] meaning that considerable attention has been brought to ensuring and improving the safety of abortion care.…”

Section: Commentmentioning

confidence: 99%

“…There were more events after medication treatment in office-based settings than hospitals and ASCs, although still within the range of published estimates. [24][25][26][27][28][29][30][31] As medication treatment does not involve procedures performed in facilities, these findings may reflect how other aspects of care, such as patient education, follow-up, and treatments provided at follow-up, may vary across facility types.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Miscarriage Treatment–Related Morbidities and Adverse Events in Hospitals, Ambulatory Surgery Centers, and Office-Based Settings

et al. 2018

View full text Add to dashboard Cite

Objective: To examine whether miscarriage treatment-related morbidities and adverse events vary across facility types. Methods: A retrospective cohort study compared miscarriage treatmentrelated morbidities and adverse events across hospitals, ambulatory surgery centers (ASCs), and office-based settings. Data on women who had miscarriage treatment between 2011-2014 and were continuously enrolled in their insurance plan for at least one year prior to and at least six weeks after treatment were obtained from a large national private insurance claims database. The main outcome was miscarriage treatment-related morbidities and adverse events occurring within six-weeks of miscarriage treatment. Secondary outcomes were major events and infections. Results: 97,374 miscarriage treatments met inclusion criteria. Most (75%) were provided in hospitals, 10% ASCs, and 15% office-based settings. 9.3% had miscarriage treatment-related events, 1.0% major events, and 1.5% infections. In adjusted analyses, there were fewer events in ASCs (6.5%) than office-based settings (9.4%) and hospitals (9.6%), but no significant difference between office-based settings and hospitals. There were no significant differences in major events between ASCs (0.7%) and office-based settings (0.8%), but more in hospitals (1.1%) than ASCs and office-based settings. There were fewer infections in ASCs (0.9%) than office-based settings (1.2%) and more in hospitals (1.6%) than ASCs and office-based settings. In analyses stratified by miscarriage treatment type, the difference 45 46 3 between ASCs and office-based settings was no longer significant for miscarriages treated with procedures. Conclusions: While there appear to be slightly more events in hospitals than ASCs or office-based settings, findings do not support limiting miscarriage treatment to particular settings.

show abstract

Section: Commentmentioning

confidence: 99%

Section: Commentmentioning

confidence: 99%

Miscarriage Treatment–Related Morbidities and Adverse Events in Hospitals, Ambulatory Surgery Centers, and Office-Based Settings

et al. 2018

View full text Add to dashboard Cite

show abstract

Treatment of first trimester miscarriage: a prospective cohort study in a large tertiary care center in Northern Italy

Lazzarin

Crippa

Tessitore

et al. 2020

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

show abstract

Medical management of miscarriage: Predictive factors of success

Lusink

Wong

Vries

et al. 2018

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Medical management of miscarriage is an acceptable option available to women, and has advantages of providing timely treatment, while avoiding exposure to surgery and anaesthesia. This retrospective cohort study aimed to determine factors predictive of successful medical management, utilising a single dose protocol of 800 µg vaginal misoprostol. In this cohort, the success rate was 67% (199/296), and smaller mean gestational sac diameter independent of gestational age predicted success (P = 0.046). Success is not significantly related to parity, miscarriage type, pelvic pain or vaginal bleeding at the outset of treatment.

show abstract

Sublingual misoprostol for management of empty sac or missed miscarriage: The first two years’ experience at a metropolitan Australian hospital

Cited by 3 publications

References 33 publications

Miscarriage Treatment–Related Morbidities and Adverse Events in Hospitals, Ambulatory Surgery Centers, and Office-Based Settings

Miscarriage Treatment–Related Morbidities and Adverse Events in Hospitals, Ambulatory Surgery Centers, and Office-Based Settings

Treatment of first trimester miscarriage: a prospective cohort study in a large tertiary care center in Northern Italy

Medical management of miscarriage: Predictive factors of success

Contact Info

Product

Resources

About